Literature DB >> 22577110

C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up.

S Bo1, L Gentile, A Castiglione, V Prandi, S Canil, E Ghigo, G Ciccone.   

Abstract

OBJECTIVE: C-peptide, a cleavage product of insulin, exerts biological effects in patients with type 1 diabetes mellitus, but its role in type 2 diabetes mellitus is controversial. Our aim was to examine the associations between fasting C-peptide levels and all-cause mortality, specific-cause mortality and the incidence of chronic complications in patients with type 2 diabetes.
DESIGN: Retrospective cohort study with a median follow-up of 14 years.
METHODS: A representative cohort of 2113 patients with type 2 diabetes mellitus and a subgroup of 931 individuals from this cohort without chronic complications at baseline from a diabetic clinic were studied.
RESULTS: Patients with higher C-peptide levels had higher baseline BMI and triglyceride and lower HDL-cholesterol values. During the follow-up, 46.1% of the patients died. In a Cox proportional hazard model, after multiple adjustments, no significant association was found between the C-peptide tertiles and all-cause mortality or mortality due to cancer, diabetes or cardiovascular diseases. In the subgroup of 931 patients without chronic complications at baseline, the incidence of microvascular complications decreased from the first to the third C-peptide level tertile, while the incidence of cardiovascular disease did not differ. The risks for incident retinopathy (hazard ratio (HR)=0.33; 95% confidence interval (CI) 0.23-0.47), nephropathy (HR=0.27; 95% CI 0.18-0.38) and neuropathy (HR=0.39; 95% CI 0.25-0.61) were negatively associated with the highest C-peptide tertile, after adjusting for multiple confounders.
CONCLUSIONS: Higher baseline C-peptide levels were associated with a reduced risk of incident microvascular complications but imparted no survival benefit to patients with type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22577110     DOI: 10.1530/EJE-12-0085

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  28 in total

1.  [Correlation between fasting C-peptide and serum uric acid in patients with type 2 diabetes mellitus].

Authors:  Qian Liang; Xin-Yu Wang; Hao-Fei Hu; Jia-Bao Lai; Wei-Li Yao; Miao-Ling Chen; Xi Rao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-04-20

Review 2.  Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.

Authors:  G R Kolar; S M Grote; G L C Yosten
Journal:  J Intern Med       Date:  2016-06-16       Impact factor: 8.989

Review 3.  C-Peptide and its career from innocent bystander to active player in diabetic atherogenesis.

Authors:  Corinna Lebherz; Nikolaus Marx
Journal:  Curr Atheroscler Rep       Date:  2013-07       Impact factor: 5.113

4.  Cholesterol and glucose profiles according to different fasting C-peptide levels: a cross-sectional analysis in a healthy cohort from the Czech Republic.

Authors:  Vladimir Kron; Miroslav Verner; Ladislav Pesl; Pavel Smetana; Jaromir Kadlec; Daniel Martinik
Journal:  J Appl Biomed       Date:  2021-10-13       Impact factor: 1.797

5.  Dietary Insulinemic Potential and Risk of Total and Cause-Specific Mortality in the Nurses' Health Study and the Health Professionals Follow-up Study.

Authors:  Yi Wan; Fred K Tabung; Dong Hoon Lee; Teresa T Fung; Walter C Willett; Edward L Giovannucci
Journal:  Diabetes Care       Date:  2022-02-01       Impact factor: 19.112

6.  Current and future management of diabetic retinopathy: a personalized evidence-based approach.

Authors:  Ryan J Fante; Thomas W Gardner; Jeffrey M Sundstrom
Journal:  Diabetes Manag (Lond)       Date:  2013-11-01

Review 7.  Physiological effects and therapeutic potential of proinsulin C-peptide.

Authors:  Gina L C Yosten; Christine Maric-Bilkan; Patrizia Luppi; John Wahren
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-09-23       Impact factor: 4.310

8.  Synergistic effects of C-peptide and insulin on low O2-induced ATP release from human erythrocytes.

Authors:  Jennifer P Richards; Alan H Stephenson; Mary L Ellsworth; Randy S Sprague
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-10-02       Impact factor: 3.619

9.  C-Peptide and vascular complications in type 2 diabetic subjects.

Authors:  Seok Man Son
Journal:  Diabetes Metab J       Date:  2012-10-18       Impact factor: 5.376

10.  Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial.

Authors: 
Journal:  Diabetes Care       Date:  2013-06       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.